Anaplastic large cell lymphoma (ALCL), a distinct subtype of T-cell non-Hodgkin lymphoma, has been the subject of vigorous research efforts over recent years. Investigations have focused on improving ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...

Implant rupture must be ruled out in the presence of a large fluid effusion surrounding the implant. Effusions that develop within 1 year of surgery may indicate a postsurgical hematoma or effusion, ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Breyanzi is approved for relapsed or refractory marginal zone lymphoma after two prior systemic therapies, showing high response rates in clinical trials. The TRANSCEND FL-MZL Cohort trial ...

The FDA has approved lisocabtagene maraleucel (Breyanzi, Bristol-Myers Squibb) for relapsed or refractory marginal zone lymphoma (MZL) in adults after at least two prior lines of systemic therapy.

Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell ...